Celularity, Inc. (CELU) is a clinical stage biotechnology company headquartered in Warren, New Jersey, USA. The company's central focus is on the advancement of innovative, off-the-shelf allogeneic therapies and biomaterial products. Essentially, it is a pioneering company, aiming to harness the unique properties of placental-derived cells and biomaterials to answer some of the most pressing medical needs.
Founded in 2016 by Robert Hariri, MD, the company is renowned for its breakthrough design of targeted placental-derived therapies. They pioneered this sector and led to a transformative perspective on treating illnesses and extending healthspan. Building on the theory that the placenta holds unique cells with significant potential for facilitating regenerative healing, Celularity intends to revolutionize the way diseases are understood and treated.
The company's portfolio includes everything from immuno-oncology, wound healing, orthopedics, and more. It consists of leading-edge placenta-derived investigational cell therapies, such as genetically modified CAR (chimeric antigen receptor) placental T-cells (PNK cells), for example. These innovative solutions could significantly enhance and target the treatment of various types of cancer.
Besides its innovative therapeutic solutions, Celularity places emphasis on the ethics behind its work. The organization derives its placental cells from ethically sourced, full-term, healthy, scheduled Cesarean section placentas.
In 2021, the company merged with GX Acquisition Corp. This move allowed Celularity to take public routes through a special purpose acquisition corporation (SPAC), consolidating its position in the competitive biotech industry and expanding its access to resources to accelerate its innovations further. This merger reflects an upward trend of utilizing SPAC to expedite commercialization in highly innovative sectors.
Celularity is led by a team of distinguished scientists, clinicians, and healthcare professionals. Its interdisciplinary team has unlocked innovative approaches using placental cells in treating a wide array of health conditions. Robert J. Hariri, the founder and CEO, is not only a neurosurgeon but also an accomplished entrepreneur in the biotechnology and aerospace sectors.
In summary, Celularity Inc. stands out as an innovator and pioneer in the biotechnology sector. The company is leveraging the untapped potential of placental-derived cells to create new solutions that will significantly impact regenerative healing, disease treatment, and overall human healthspan. It's no wonder then that the company's advances have attracted attention in the biotechnology sector, showcasing just how much potential and upside there is to what they're doing. Moreover, the company's dedication to ethical practices adds more credibility to its operations, ensuring that innovation and integrity can indeed co-exist.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Philip Alan Barach, a director and 10% stakeholder of Celularity Inc (NASDAQ:CELU), has updated his holdings by amending existing convertible notes and warrants and acquiring new securities. These transactions, detailed in a September 25, 2026, Form 4 filing, include reducing conversion and exercise prices, extending maturity and expiration dates, and purchasing new convertible notes and warrants. All securities are held indirectly through the Philip and Daniele Barach Family Trust.
Celularity (NASDAQ:CELU) is currently in focus after providing an update regarding its Nasdaq listing compliance. This development highlights the company's activities in cell therapy development, financing flexibility, and adherence to listing standards. The article emphasizes that execution, customer response, and disciplined follow-through will be crucial for the company's long-term relevance.
Celularity Inc. (CELU) has received a notice from Nasdaq due to its Class A common stock trading below $1.00 for 30 consecutive business days, failing to meet the minimum bid price requirement. The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, with the possibility of an extended grace period. Analysts currently rate CELU as a Buy with a $6.00 price target, despite Spark's AI Analyst categorizing it as Neutral due to weak financial health and bearish technical signals.